Lilly Commits 780,000 Additional Vials of Insulin to Life for a Child
Eli Lilly and Company has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International Diabetes Federation (IDF) is the global advocate for people with diabetes, representing 230 national diabetes associations in 170 countries and territories.
Lilly's new commitment builds on the company's previous donation of 800,000 vials of insulin over the past 6 years, which reached more than 14,000 children in 34 countries. During the next 3 years, Lilly will donate approximately 260,000 vials of insulin each year to the Life for a Child program. This commitment will allow Life for a Child to continue providing treatment for children in the countries where the program currently operates and to increase the amount of insulin supplied for distribution.
Lilly is the sole provider of insulin to the IDF's Life for a Child program. The original donation of 800,000 vials represented Lilly's largest-ever product donation at the time. This new development extends Lilly's total commitment to Life for a Child to nearly 1.6 million vials of insulins.
"We know that a diagnosis of diabetes is a monumental event for any child and family. But, sadly, in many lower- and middle-income countries, that diagnosis all too often means no future at all," said Graham Ogle, Life for a Child general manager. "Lilly's donation of insulin offers continued hope to children and families in need who are trying to manage type 1 diabetes in very challenging conditions."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.